CanSino Receives Another Strong Boost
配信日時: 2024-10-09 21:29:00
HONG KONG, Oct 9, 2024 - ( JCN Newswire ) - HONG KONG, Oct 9, 2024 - (ACN Newswire) - CanSino Biologics Inc. ("CanSinoBIO" or "the Company") has announced a milestone in its fight against polio. The company has received an additional financial boost, securing a grant exceeding US$17 million to propel its recombinant poliovirus vaccine ("VLP-Polio") project forward. This new funding, which builds on the initial funding received in October 2023, also encompasses potential related combined vaccine candidates.
In addition to the grant, CanSinoBIO has also obtained approval to start phase I/II clinical trials for the VLP-Polio vaccine in Indonesia, focusing on infants and toddlers in certain ages. This marks an important step forward in ensuring VLP-Polios safety and efficacy for the most vulnerable population.
Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO, expressed his gratitude for the continued support, stating, We are deeply honored by the foundation's ongoing trust and support. This recognition not only supports our innovation and production capabilities but also advances our commitment to improving global public health. We believe our innovative VLP-Polio vaccine will play a pivotal role in the global effort to eradicate polio.
Receives Over US$17 Million from Bill & Melinda Gates Foundation to Accelerate VLP-Polio Vaccine Development
This funding will further accelerate the clinical progress of the VLP-Polio vaccine, while the introduction of this vaccine candidate is expected to fill a gap in the market.
Leveraging the Company's profound expertise in protein structure design and virus-like particle (VLP) assembly technology, the VLP-Polio vaccine stands as a non-infectious alternative which eliminates the need for live viruses. This pioneering approach promises superior safety with comparable or superior immunogenicity, earning recognition from the World Health Organization ("WHO") as a pivotal tool for future polio eradication, particularly in the post-eradication era. This vaccine candidate holds immense significance in the global endeavor to control and eliminate polio, safeguarding millions of children and families from this devastating condition.
CanSinoBIO has been an avid participant in the WHO's polio eradication strategy, attentively tracking global disease prevention requirements. The funding received will further bolster CanSinoBIO's capacity to deliver innovative, high-quality, and affordable vaccines worldwide, aligning with the ambition of making advanced vaccine products accessible to all.
スポンサードリンク
「ビジネス全般」のプレスリリース
- ヘアミルク・オイルについての意識調査10/09 17:48
- (お知らせ)仙台工場で「地域ふれあいフェア2024」を開催10/09 17:30
- 世界最大の年次金融イベント「世界投資者週間2024」のフォーラム、盛大に開催(台湾・台北)10/09 15:06
- 「ビジネス全般」のプレスリリースをもっと読む
スポンサードリンク
最新のプレスリリース
- CanSino Receives Another Strong Boost10/09 21:29
- インベスコ・アセット・マネジメント株式会社「インベスコ 世界厳選株式オープン【愛称:世界のベスト】」6ファンド合計で運用資産残高1兆7,000億円を達成10/09 19:40
- 地域防災の新たな一歩 名古屋市 片平学区防災安心まちづくり委員会と「大規模災害時における地域と事業所との支援協力に関する覚書」を締結10/09 19:15
- 世界500本限定!『SPINNAKER』、スコットランドの未確認動物「ネッシー」をデザインした『FLEUSS - Scottish Watches NESSIE LIMITED EDITION』発売。10/09 19:15
- ~街のインフラとなる将来像に向けて、川崎市道を空中配送ロボットが横断~パナソニック ホールディングス、東急、UR都市機構空中配送ロボット実証実験を次のステージへ10/09 19:15
- 最新のプレスリリースをもっと見る